Literature DB >> 31522129

Eltrombopag treatment for severe refractory thrombocytopenia caused by pembrolizumab.

Peng Song1, Li Zhang2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31522129     DOI: 10.1016/j.ejca.2019.08.003

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  5 in total

Review 1.  Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.

Authors:  Atsuto Mouri; Kyoichi Kaira; Ayako Shiono; Y U Miura; Hiroshi Kagamu
Journal:  In Vivo       Date:  2020 Mar-Apr       Impact factor: 2.155

2.  Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review.

Authors:  Xiaolin Liu; Xiuju Liang; Jing Liang; Yan Li; Jun Wang
Journal:  Front Oncol       Date:  2020-12-07       Impact factor: 6.244

3.  Efficacy and Immunomodulating Properties of Eltrombopag in Aplastic Anemia following Autologous Stem Cell Transplant: Case Report and Review of the Literature.

Authors:  Marta Bortolotti; Loredana Pettine; Anna Zaninoni; Giorgio Alberto Croci; Wilma Barcellini; Bruno Fattizzo
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-30

Review 4.  [Diagnosis and Treatment Recommendation and Exploration for Critical and Refractory Adverse Effects Related to Immunocheckpoint Inhibitors].

Authors:  Hanping Wang; Peng Song; Xiaoyan Si; Xiaoxiao Guo; Yue Li; Jiaxin Zhou; Lian Duan; Li Zhang; Mengzhao Wang; Li Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-10-20

Review 5.  Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer: Case Report and Literature Review.

Authors:  Wang Xie; NaNa Hu; LeJie Cao
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.